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Background: There is a higher prevalence of obesity in individuals with mental disorders compared to the general
population. The results of several studies suggested that weight reduction in this population is possible following
psycho-educational and/or behavioural weight management interventions. Evidence of the effectiveness alone is
however inadequate for policy making. The aim of the current study was to evaluate the cost-effectiveness of a
health promotion intervention targeting physical activity and healthy eating in individuals with mental disorders.
Methods: A Markov decision-analytic model using a public payer perspective was applied, projecting the one-year
results of a 10-week intervention over a time horizon of 20 years, assuming a repeated yearly implementation of the
programme. Scenario analysis was applied evaluating the effects on the results of alternative modelling assumptions.
One-way sensitivity analysis was performed to assess the effects on the results of varying key input parameters.
Results: An incremental cost-effectiveness ratio of 27,096€/quality-adjusted life years (QALY) in men, and 40,139€/QALY
in women was found in the base case. Scenario analysis assuming an increase in health-related quality of life as a result
of the body mass index decrease resulted in much better cost-effectiveness in both men (3,357€/QALY) and women
(3,766€/QALY). The uncertainty associated with the intervention effect had the greatest impact on the model.
Conclusions: As far as is known to the authors, this is the first health economic evaluation of a health promotion
intervention targeting physical activity and healthy eating in individuals with mental disorders. Such research is
important as it provides payers and governments with better insights how to spend the available resources in the most
efficient way. Further research examining the cost-effectiveness of health promotion targeting physical activity and
healthy eating in individuals with mental disorders is required.
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The prevalence of overweight (Body Mass Index 25-
29.9 kg/m2) and obesity (Body Mass Index ≥30 kg/m2)
has increased in the last three decades and has be-
come a serious global public health concern [1]. Obesity
is a risk factor for the development of important non-
communicable diseases including type 2 diabetes, coron-
ary heart disease (CHD), stroke, and certain cancers such* Correspondence: nick.verhaeghe@ugent.be
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article, unless otherwise stated.as colon cancer and breast cancer [2] leading to con-
siderable healthcare expenditures [3]. Obesity is also
associated with reduced health-related quality of life
(HRQOL) [4] and with reduced life expectancy [5].
There is conclusive evidence that the burden of weight
gain is even higher in individuals with mental disor-
ders (MD) than in the general population [6,7]. Im-
portant factors contributing to the high prevalence of
overweight and obesity in people with MD are side ef-
fects of especially second generation antipsychotic drugs
[8], a lack of regular physical activity (PA) and unhealthy
eating behaviour [9].tral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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and healthy eating should be integrated into the daily
care of individuals with MD. The results of previous re-
search suggested that weight loss following behavioural
and/or psycho-educational programmes in MD patients
is possible [10,11]. Evidence on the effectiveness alone of
such interventions is yet insufficient for policy making.
Healthcare budgets are limited, hence policy makers are
facing the problem how to set priorities in the allocation
of healthcare resources to medical or public health inter-
ventions. Knowledge on this can be obtained by perform-
ing health economic evaluations of weight reduction
programmes. The evidence derived from such research
can assist regulatory bodies and health insurers establish-
ing priorities within cost-constrained healthcare budgets.
In the general population, health economic evaluations
of health promotion programmes targeting PA [12] and
healthy eating [13] yield mixed evidence on the cost-
effectiveness of such interventions. In mental health care,
such trials are lacking [14].
The aim of the current study was to evaluate the cost-
effectiveness of a health promotion programme targeting
PA and healthy eating in individuals with MD living in
sheltered housing in the Flanders region in Belgium. De-
tails on the design and results of the effectiveness study
are described elsewhere [15]. In brief, the study design
consisted of a cluster preference randomised controlled
trial and was conducted in sheltered housing organi-
sations (SHOs) in the Flanders region (Belgium). The
intervention group included 16 SHOs (n = 201 individ-
uals), while the control group included eight SHOs (n = 83
individuals). The health promotion intervention was based
on an existing programme aimed at the general population
developed by the Flemish Institute of Health Promotion
and Disease Prevention [16]. As the target population
of our study consisted of individuals with MD, some
adjustments to the programme were made. The study
consisted of a 10-week group-based and individually-
based health promotion intervention, followed by a
6-month follow-up period. Individuals in the intervention
group received the 10-week programme on top of their
usual treatment, while those in the control group only re-
ceived treatment as usual. The intervention was delivered
by one or more mental health nurses working in the
intervention SHOs. All participants in the intervention
group received the same information in the same format
comprising: (i) ten psycho-educational and behavioural
group-based sessions in a 10-week period, (ii) group-
based exercise in the same 10-week period (weekly 30’
supervised walking sessions), and (iii) individual support
from the mental health nurses during the 10-week inter-
vention. Data were collected at baseline, at ten weeks
(end of the intervention) and after a six-month follow-up
period.Methods
Decision-analytic model
An age- and gender-dependent Markov decision-analytic
model applying a public payer perspective was used to
predict health outcomes and costs for the intervention
and control arm. Health outcomes were expressed as
quality-adjusted life years (QALYs) and calculated by
multiplying the utility level (a HRQOL weight) for a
given disease status with the number of years an individ-
ual is living with the disease. A utility of 1 equals perfect
health, while 0 stands for death. In the cost dimension,
both the programme costs and the disease costs were
accounted for. Dividing the difference in costs between
the intervention and the control group (=incremental
costs) by the difference in QALYs between the two
groups (=incremental QALYs) results in the incremental
cost-effectiveness ratio (ICER) calculated as: ICER =
(costI– costNI)/(QALYI-QALYNI), where ‘I’ stands for inter-
vention and ‘NI’ for no intervention.
The Markov model was based on a published model
[17] and further developed using ©Microsoft Excel
(Microsoft Corporation, Redmond, WA, US) to account
for the specific context and characteristics of the current
study. Nine possible states were included in the model
(Figure 1): (i) population at risk (‘at risk’), (ii) type 2 dia-
betes (‘diabetes’), (iii) CHD, first year (‘CHD 1’), (iv) CHD,
following years (‘CHD 1+’), (v) stroke, first year (‘stroke 1’),
(vi) stroke, following years (‘stroke 1+’), (vii) colon cancer,
first year (‘colon cancer 1’), (viii) colon cancer, following
years (‘colon cancer 1+’), and (ix) dead (‘dead’). The time
horizon of the model was 20 years including 20 one-year
periods (called ‘cycles’).
All individuals start in the ‘at risk’ state. During each
cycle, an individual has a risk to move to one of the dis-
ease states or to ‘dead’. Once an individual is suffering
from diabetes, he or she can only remain in that state or
move to the ‘dead’ state. Patients suffering from stroke
move to the ‘stroke 1’ state. Once a patient has had a
stroke, he or she can only move to the ‘stroke 1+’ state
or to ‘dead’. Patients who have had a fatal stroke move
to the ‘dead’ state after being in the ‘stroke 1’ state for
one cycle. Patients in the ‘stroke 1+’ state can only stay
in that state or move to ‘dead’. Transitions throughout
the model for patients suffering from CHD or colon
cancer are analogous as for stroke. CHD includes myo-
cardial infarction and stable or unstable angina. Once a
patient enters the ‘dead’ state, no further transitions are
possible, as this is the final state.
Clinical data inputs: disease and mortality transition
probabilities
First, the risk of developing diabetes [18,19], stroke
[19,20], CHD [18,19], and colon cancer [21] for the gen-
eral population was calculated. Second, the calculated
At risk
Colon cancer  1 
Diabetes
Colon cancer 1+
Stroke 1
Stroke 1+
CHD 1
CHD 1+
Dead
Figure 1 Markov decision-analytic model.
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risk (RR) factor as it is known that individuals with MD
are at a greater risk of having diabetes (RR 1.77) [22],
stroke (RR 1.77) [23], CHD (RR 18-49 years: 1.42; RR
50-75 years: 1.01) [23], and colon cancer (RR 2.90) [24].
The transition probability from diabetes to colon cancer
was calculated by multiplying the transition from ‘at risk’
to diabetes with a RR of 1.33 [25], since diabetic patients
have a greater risk of developing colon cancer compared
to those without diabetes. The mortality probabilities
were obtained from the literature or they were calculated
by multiplying national mortality probabilities [26] with
the RR of dying from one of the diseases included in the
model. Ubink-Veltmaat et al. [27] found a 40% mortality
increase in people with diabetes compared to the general
Dutch population. A twofold mortality risk was found
among stroke patients compared to the Flemish general
population [20]. Age- and sex-specific CHD mortality
was derived from a study on CHD-mortality in the
Netherlands [28]. Colon cancer mortality was obtained
from the ‘Cancer survival in Belgium 2004-2008’ report
[29]. An overview of the transition probabilities used in
the model can be found in Table 1.
Effect of the health promotion intervention
A simulation of the evolution of the cohort was made
based on the change in Body Mass Index (BMI) between
the intervention group and the control group and the
age- and gender-dependent associated risk of devel-
oping BMI-related diseases. The effectiveness study [15]
showed a small but significant difference in BMI change
of 0.20 kg/m2 between the two study groups. The resultsof previous studies suggested that a reduction of one
BMI unit results in a decreased risk of developing dia-
betes (men: 13.0%, women: 11.0%) [30], CHD (men: 4.7%,
women: 5.7%) [31], stroke (men: 6.0%, women: 8.5%)
[32,33], and colon cancer (men: 5.2%, women: 2.0%) [34].
The risk reductions associated with BMI decrease applied
in the Markov model were subsequently calculated using
the data derived from these studies (Table 2).
Cost data input: disease costs and intervention costs
A public payer perspective was considered including
only direct medical costs (Table 2). The costs are
expressed in the year 2011 euros. The total diabetes
cost was calculated accounting for the proportion of
diabetic patients with no complications, micro vascular
and/or macro vascular complications [35]. For stroke
and CHD, first year costs and following year costs were
taken separately into account as the cost related to a
newly diagnosed cardiovascular disease was found to be
different from the cost for those already suffering lon-
ger from stroke or CHD [36-38]. The colon cancer cost
was obtained from a health economic evaluation of ex-
ercise in the prevention of cardiovascular and other
prosperity diseases [36]. Future costs were discounted
at 3% [39]. The intervention cost/patient included the
use of a pedometer (13.70€), staff cost (20.57€), admin-
istrative costs (0.48€), and the intervention manual cost
(0.25€). The staff cost/participant was calculated taking
into account the total intervention duration time, the
number of participating SHOs and individuals, and the
time investment (hourly wages). An effective duration
of five years was considered for the pedometers, so this
Table 1 Age- and gender- dependent probabilities (%) for developing diabetes, stroke, coronary heart disease or colon
cancer and associated mortality (%)
Diabetes Coronary heart disease Stroke Colon cancer
Overall
mortality
Incidence
Case fatality rate
Incidence
Case fatality rate
Incidence Case fatality
rate
1st year Follow up 1st year Follow up Incidence Case fatality
rate
Age
(years)
M W M W M W M W M W M W M W M W M W M W M W
20-24 0.06 0.05 0.12 0.04 0.01 0.01 5.50 7.30 4.87 7.74 0.02 0.02 13.00 25.00 0.16 0.06 0.01 0.01 6.62 5.67 0.08 0.03
25-29 0.10 0.08 0.13 0.06 0.02 0.02 5.50 7.30 4.87 7.74 0.03 0.03 13.00 25.00 0.18 0.08 0.01 0.01 6.62 5.67 0.09 0.04
30-34 0.17 0.14 0.13 0.06 0.05 0.03 5.50 7.30 4.87 7.74 0.05 0.04 13.00 25.00 0.18 0.09 0.01 0.01 6.62 5.67 0.09 0.04
35-39 0.28 0.23 0.19 0.11 0.10 0.05 5.50 7.30 4.87 7.74 0.07 0.06 13.00 25.00 0.26 0.15 0.03 0.03 6.62 5.67 0.12 0.07
40-44 0.48 0.39 0.26 0.16 0.19 0.08 5.50 7.30 4.87 7.74 0.11 0.09 13.00 25.00 0.36 0.23 0.04 0.04 6.62 5.67 0.15 0.10
45-49 0.78 0.63 0.44 0.27 0.35 0.13 5.50 7.30 4.87 7.74 0.16 0.13 13.00 25.00 0.61 0.38 0.09 0.09 6.62 5.67 0.24 0.16
50-55 1.18 0.96 0.74 0.44 0.41 0.16 5.50 7.30 4.87 7.74 0.25 0.20 36.00 18.00 1.03 0.63 0.16 0.16 7.70 6.89 0.39 0.27
56-59 1.65 1.34 1.19 0.64 0.63 0.27 15.30 17.90 13.56 18.97 0.37 0.30 36.00 18.00 1.65 0.90 0.26 0.26 7.70 6.89 0.61 0.37
60-64 2.08 1.69 1.82 0.98 0.89 0.41 15.30 17.90 13.56 18.97 0.55 0.44 24.00 23.00 2.53 1.39 0.37 0.38 7.70 6.89 0.90 0.54
65-69 2.46 2.00 2.58 1.36 1.17 0.62 15.30 17.90 13.56 18.97 0.83 0.67 24.00 23.00 3.59 1.93 0.60 0.60 9.77 8.91 1.28 0.74
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five years.
Health-related quality of life (utilities)
The ‘at risk’ utility, i.e. the utility for patients without
a history of one of the diseases included in the
model was set at 0.71 [40]. The disease-specific util-
ities were derived from a health economic evaluation
of a community-based PA intervention [17] (Table 2).
QALYs were calculated by multiplying the utilities with
the number of life years an individual is living with one
of the diseases included in the model. Future QALYs
were discounted at 1.5% [39].
Scenario analysis and sensitivity analyses
Health economic evaluations are frequently character-
ized by some degree of uncertainty or methodological
considerations [41]. In the current study, scenario ana-
lyses and sensitivity analyses were performed to tackle
this uncertainty. In the scenario analysis, four alternative
modelling assumptions were assessed. First, full com-
pliance with the intervention was assumed. For this
analysis, a mean change of 0.33 kg/m2 (i.e. the mean
BMI change of the participants who completed the
programme) [15] was considered. In a second scenario,
the effects on the costs and the QALYs of offering the
programme twice a year maintaining a mean BMI change
of 0.20 kg/m2 was analysed. In the base case analysis, no
increase in HRQOL as a result of the BMI decrease was
accounted for. So, in a third scenario, in the intervention
group, a utility gain of 0.021 per unit BMI decrease was
assumed based on the findings of a study of valuing
HRQOL in diabetes patients [42]. In that study, a utilityloss of 0.021 per unit BMI increase was accounted for.
So, we assumed a utility gain of 0.021 per unit BMI de-
crease. In the base case analysis, a 20-year time horizon
was used maintaining the same intervention effect. As a
fourth scenario analysis, a more conservative analysis was
conducted considering a five-year time horizon. One-way
sensitivity analyses made it possible to assess the effects
of key input parameters (intervention cost and effect,
disease costs, and RR reductions of the diseases associ-
ated with a BMI decrease) on the ICER, by varying
them separately. A probabilistic sensitivity analysis was
performed to assess the uncertainty for the key input
parameters by varying them concurrently. Cost data
were assumed to follow a gamma distribution, utilities
follow a beta distribution and risk reductions a lognor-
mal distribution [43].
Ethics
The study was in compliance with the Helsinki Declar-
ation and permission to perform the study was obtained
from the Ethics Committee of the University Hospital of
Ghent.
Results
Base case analysis
For the treatment as usual group, the average QALYs
amounted to 11.59 and 12.04 with a cost of 8,352€ and
7,688€ for men and women respectively. The implemen-
tation of the health promotion intervention resulted in a
limited QALY gain of 0.01 in both men and women. The
total discounted costs in the intervention group were
8,579€ in men and 7,951€ in women, resulting in a delta
cost between intervention and no intervention of 228€
Table 2 Input parameters for the Markov decision-analytic
model - base case
Parameter Base case SE Distribution Reference
RR reduction (%)
Diabetes - men 2.60 0.003 lognormal [30]
Diabetes - women 2.20 0.002 lognormal [30]
CHD - men 0.94 0.001 lognormal [31]
CHD - women 1.14 0.001 lognormal [31]
Stroke - men 1.20 0.001 lognormal [32]
Stroke - women 1.70 0.002 lognormal [33]
Colon cancer - men 1.04 0.001 lognormal [34]
Colon cancer - women 0.40 0.001 lognormal [34]
Cost/year data input (€)1
Diabetes 3,312 331 gamma [35]
CHD first year 4,386 439 gamma [36-38]
CHD subsequent years 1,183 118 gamma [36-38]
Stroke first year 13,319 1,332 gamma [36]
Stroke subsequent years 4,756 476 gamma [36]
Colon cancer 9,575 958 gamma [36]
Intervention cost2 35 3.50 gamma [15]
Intervention cost3 21 2.13 gamma [15]
Utilities
At risk 0.71 0.04 beta [40]
Diabetes 0.63 0.06 beta [17]
CHD 1 0.47 0.05 beta [17]
CHD 1+ 0.56 0.06 beta [17]
Stroke 1 0.50 0.05 beta [17]
Stroke 1+ 0.50 0.05 beta [17]
Colon cancer 1 0.64 0.06 beta [17]
Colon cancer 1+ 0.64 0.06 beta [17]
Dead 0
RR, relative risk; CHD, coronary heart disease.
1expressed in the year 2011 euros; 2intervention cost for the years 1,6,11,16.
3intervention cost for the other years.
Verhaeghe et al. BMC Public Health 2014, 14:856 Page 5 of 9
http://www.biomedcentral.com/1471-2458/14/856and 263€ in men and women respectively. This resulted
in an ICER of 27,096€/QALY in men and 40,139€/QALY
in women (Table 3).
Scenario analysis of alternative modelling assumptions
Applying the scenario of full compliance with the
programme resulted in an ICER of 10,241€/QALY in men
and 17,857€/QALY in women. An increase in HRQOL
as a result of the BMI decrease resulted in an ICER of
3,357€/QALY in men and 3,766€/QALY in women. Worse
results were found in the scenario offering the programme
twice a year (Table 3). Taking into account a five-year time
horizon resulted in an ICER of 190,647€/QALY in men
and 266,700€/QALY in women.Sensitivity analyses
The results of the one-way sensitivity analyses are shown
using Tornado diagrams (Figure 2a and b). From this
figure it can be concluded that the model is most sensi-
tive to the intervention effect and to the intervention
cost in both men and women. Varying other input pa-
rameters had less influence on the results. The findings
of the probabilistic sensitivity analysis are shown in cost-
effectiveness planes (Figure 3a and b). The points to the
right of the threshold line refer to a cost-effectiveness
ratio less than 30,000€/QALY. Based on 10,000 simula-
tions, 95% credible intervals (CI) could be generated.
The health promotion programme resulted in an average
QALY gain of 0.008 (95% CI 0.003-0.014) at an average
cost of 221€ (95% CI 168€-278€) in men and in an aver-
age QALY gain of 0.007 (95% CI 0.002-0.011) at an aver-
age cost of 256€ (95% CI 201€-316€) in women. In men,
an average ICER of 26,336€/QALY (95% CI 14,439-
83,209€/QALY) was found, while in women the ICER
was 39,094€/QALY (95% CI 21,573-120,541€/QALY).
Discussion
The aim of the study was to evaluate the cost-effectiveness
of a health promotion programme targeting PA and
healthy eating in individuals with MD living in shel-
tered housing in the Flanders region (Belgium). A
Markov decision-analytic model providing informa-
tion on the costs and on the health effects (expressed
as QALYs) related to the programme was used. The
base case analysis showed an ICER of 27,096€/QALY
in men and 40,139€/QALY in women. Assuming a cost-
effectiveness threshold of about 30,000€/QALY in Belgium
as recommended by the Belgian Healthcare Knowledge
Centre [44], it can be concluded that the intervention was
cost-effective in men but not in women. Mixed results
were identified from the scenario analyses. The most
promising outcome was found when an increase in
HRQOL associated with a BMI decrease was assumed.
The model was most sensitive to the input parameters
‘intervention effect’ and ‘intervention cost’ as demon-
strated with the one-way sensitivity analyses.
In the base case, the health promotion programme
was found to be borderline cost-effective in men and not
cost-effective in women. The explanation for this result
is likely the fact that a limited, although statistically sig-
nificant, BMI change of 0.20 kg/m2, drawn from the
effectiveness study [15], was used to calculate the risk
reductions for the diseases included in the model. This
was confirmed by the one-way sensitivity analysis re-
sults, identifying the ‘intervention effect’ as the input
parameter most influencing the outcome. The limited
change in BMI may be explained by the relatively short
intervention duration of ten weeks. A more promising
result was found if a BMI change of 0.33 kg/m2 assuming
Table 3 Cost-effectiveness results in men and women (base case and scenario analysis)
Control Intervention
Δ QALY Δ Cost (€) ICER (€/QALY)QALYs Cost (€) QALYs Cost (€)
Men
Base case 11.59 8,352 11.60 8,579 0.01 228 27,096
Scenario 1 11.59 8,352 11.61 8,494 0.01 142 10,241
Scenario 2 11.59 8,352 11.60 8,938 0.01 586 69,754
Scenario 3 11.59 8,352 11.66 8,579 0.07 228 3,357
Scenario 4 4.05 980 4.05 1,095 0.00 115 190,647
Women
Base case 12.04 7,688 12.05 7,951 0.01 263 40,139
Scenario 1 12.04 7,688 12.05 7,881 0.01 193 17,857
Scenario 2 12.04 7,688 12.05 8,320 0.01 632 96,567
Scenario 3 12.04 7,688 12.11 7,951 0.07 263 3,766
Scenario 4 4.08 807 4.08 926 0.00 119 266,700
Scenario 1, full compliance with the programme; scenario 2, offering the programme twice a year.
Scenario 3, increase in quality of life as a result of the BMI-decrease in the intervention group.
Scenario 4: time horizon of 5 years.
ICER, Incremental Cost-Effectiveness Ratio; QALY, Quality Adjusted Life Year.
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can yet be discussed to what extent full compliance with
the programme is achievable in populations with MD. Pre-
vious qualitative research identified a number of barriers
hampering the participation of psychiatric patients in
health promotion interventions [45]. Applying the scenarioFigure 2 One-way sensitivity analysis: effects on cost/QALY.
(a) Men. (b) Women.in which an increase in HRQOL as a result of BMI de-
crease was assumed, resulted in a conclusive cost-effective
outcome in both men and women. This result must how-
ever be interpreted cautiously. Research on the effects of
weight loss on HRQOL in people with MD is scarceFigure 3 Probabilistic sensitivity analysis. (a) Men. (b) Women.
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ciated with an increase in HRQOL [14]. A clearly not
cost-effective result was observed considering a five-year
time horizon. If the health effects are expressed as life
years(LY) gained, the intervention resulted in 0.01 LY
gained in men (intervention: 16.62 LY, control: 16.61 LY)
and in women (intervention: 17.18 LY, control: 17.17 LY)
(data not shown).
In the current healthcare environment, there is grow-
ing need on health economic evaluations of such pro-
grammes because this can assist regulatory bodies
and health insurers establishing priorities within cost-
constrained healthcare budgets. In mental health care,
health economic research predominantly focused on cost-
effectiveness analyses of psychopharmacological drugs
[46] and mental health promotion and MD prevention
[47]. Although the need for health economic evaluations
of health promotion programmes targeting PA and
healthy eating in mental health care was already ad-
dressed [48], such studies are lacking [14]. A uniform 70%
to 130% uncertainty was used in the one-way sensitivity
analysis, since the main reason to perform this analysis
was to gain insight in those parameters most influencing
the study outcome and not to assess the implications on
the study outcome of uncertainty in the parameters. The
full uncertainty around the input parameters was reflected
with the probabilistic sensitivity analysis [41].
Some limitations and considerations need to be ad-
dressed. First, a 20-year time horizon assuming that the
10-week health promotion programme was repeated
every year maintaining the same BMI change was consid-
ered. Studies evaluating the long-term effects of health
promotion targeting PA and healthy eating in individuals
with MD are yet lacking [14]. So, uncertainty exists con-
cerning the long-term effects on BMI of offering such a
programme once a year. The time horizon used in the
current study was based on the time horizon used in a
previous health economic evaluation of a community-
based PA intervention [17]. We are aware that the time
horizon is excessive on the basis of evidence found
following a 10-week intervention the benefits of which
disappeared at six months [15]. There is only limited evi-
dence suggesting that health promotion targeting PA and
healthy eating can result in longer-term weight loss.
Unick et al. [49] found that weight loss was possible in
overweight and obese diabetes patients following a re-
peated health promotion intervention targeting PA and
healthy eating during a 4-year time period. Nevertheless,
there is no evidence supporting that a repeated health
promotion programmme would maintain the same effect
during a 20-year time period. So, as a more conservative
approach, an additional analysis was performed consider-
ing a five-year time period resulting in a clearly not cost-
effective outcome in both men and women. On the otherhand, the use of extensive time horizons in health eco-
nomic evaluations is quite common [17,36,50]. Second,
the model is a simplification of real life because model
complexity prevented us to for example allow some com-
binations of disease states. Efforts to approximate the
reality were yet applied, such as the inclusion of a transi-
tion probability from diabetes to colon cancer. No transi-
tions from diabetes to CHD and stroke were possible, but
the proportion of macro vascular complications such as
CHD and stroke [51] was accounted for in the calcula-
tion of the diabetes cost. Costs related to follow-up after
being diagnosed with one of the diseases included in the
model were accounted for in the follow-up states (the
states ‘1+’ in the Markov model). Third, the disease tran-
sition and mortality probabilities were retrieved from the
literature and nationally available data. For some prob-
abilities, national data were absent, so data from other
countries was used. This may have resulted in an under-
estimation or overestimation of some probabilities in-
cluded in the model. A utility of 0.71 [40] found in a
sample of schizophrenia and major depressive disorder
patients was used for the ‘at risk’ state. We are aware that
utilities may differ according to the psychiatric diagnosis
[52]. Nevertheless, the use of the 0.71 utility in our study
is likely to be a reasonable reflection of the reality as
about two-thirds of our study population consisted of
schizophrenia and mood disorder patients. It is also im-
portant to note that utility weights may vary according to
the measurement instrument being used. Lamers et al.
[53] compared the use of the EQ-5D and the SF-6D
questionnaires in a MD patients sample. It was found
that the use of the EQ-5D resulted in larger health gains
and consequent lower cost-utility ratios compared with
the SF-6D. In one of the scenario analyses, an increase in
HRQOL due to a BMI decrease was assumed. It can be
argued that there is a risk of double counting of the util-
ity benefit since the risk reduction of disease already
incorporates a gain in QALYs. In the scenario analysis,
the utility increase was only accounted for in the inter-
vention group in the ‘at risk’ state and not in the different
disease states.
Conclusions
In conclusion, as far as is known to the authors, this is
the first study assessing the cost-effectiveness of a health
promotion intervention targeting PA and healthy eating
in individuals with MD. It was found that the health
promotion intervention is likely to be cost-effective on
the long-term if the programme would be repeated every
year maintaining the same effect. This rather optimistic
finding must be cautiously interpreted since there is no
evidence supporting the long-term effectiveness of such
interventions on BMI. Further research examining the
cost-effectiveness of health promotion interventions in
Verhaeghe et al. BMC Public Health 2014, 14:856 Page 8 of 9
http://www.biomedcentral.com/1471-2458/14/856populations with MD is required. Further health eco-
nomic evaluations of health promotion programmes is
also required accounting for other study conditions such
as individually-based programmes, programmes with
longer duration and/or delivered in other settings. Such
research has a substantial social value because healthcare
budgets are limited, hence policy makers are facing the
problem how to set priorities in the allocation of health-
care resources to medical or public health interventions.
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